Omnicell (OMCL) stock is soaring 13.64% in pre-market trading following the release of its impressive second-quarter 2025 financial results and raised full-year guidance. The medication management technology company significantly outperformed analyst expectations, demonstrating robust growth and improved profitability.

For Q2 2025, Omnicell reported revenues of $291 million, up 5% year-over-year and surpassing the consensus estimate of $275.24 million. The company's adjusted earnings per share (EPS) came in at $0.45, substantially beating the expected $0.21. This strong performance was driven by increased demand for connected devices, technical services, SaaS and Expert Services, and consumables revenues.

Adding to investor optimism, Omnicell raised its full-year 2025 guidance for total revenues, non-GAAP EBITDA, and non-GAAP EPS. The company now expects 2025 adjusted EPS in the range of $1.40 to $1.65 and total revenue between $1.130 billion and $1.160 billion. Furthermore, Omnicell provided a positive outlook for Q3, projecting revenues between $290 million and $300 million, above the consensus of $284.1 million. The company's ongoing innovation efforts, including the introduction of new solutions such as the MedTrack RFID Line and MedVision inventory management solution, are expected to contribute to future growth and maintain Omnicell's leadership position in medication management technology.